# Dr. Matthew Dallimore Appointed President of Dynasil - Dynasil Corporation
Canonical URL: https://biopharmsignal.com/news/DYSL/dr-matthew-dallimore-appointed-president-of-dynasil-dynasil-corporation-61b6cb48
Ticker: DYSL
Company: Dynasil
Source: Dynasil
Published: 2026-07-09 00:01 EST
Original Source URL: https://www.dynasil.com/about/news/
## Summary

Concord, Massachusetts – October 8, 2024 – The Board of Directors of Dynasil Corporation of America (“Dynasil”) is pleased to announce the appointment of Dr. Matthew Dallimore as President of Dynasil on October...

## Article Body
Concord, Massachusetts – October 8, 2024 – The Board of Directors of Dynasil Corporation of America (“Dynasil”) is pleased to announce the appointment of Dr. Matthew Dallimore as President of Dynasil on October 1, 2024.

“Dr. Dallimore has been leading Radiation Monitoring Devices, Inc (“RMD”) as President since 2022,” said Peter Sulick, Chairman and CEO of Dynasil. “We are excited to work with Dr. Dallimore to grow our businesses, in particular, the growing partnership between RMD and Hilger Crystals, Ltd (“Hilger”).”

“I am excited to leverage the unique strengths within the Dynasil team, combining the exceptional research and materials science expertise of RMD with the advanced high-tech manufacturing capabilities at Hilger,” said Dr. Dallimore. “By fostering this collaboration, as well as others, we will continue to drive innovation and deliver cutting edge products for our partners.”

“Dr. Dallimore has already facilitated the growth of the working relationship between Hilger and RMD”, said Jim Telfer, Managing Director of Hilger. “Our customers are already benefitting from the new products and expertise we have developed under Dr. Dallimore’s leadership.”

Prior to becoming President of RMD, Dr. Dallimore was a founder of Symetrica, where he served for two decades in various roles including Lead Scientist, Program Manager, General Manager, Director, and Chief Technology Officer.

About Dynasil

Dynasil Corporation of America develops and manufactures optics and photonics products, optical detection and analysis technology and components for the homeland security, medical and industrial markets. Combining world-class expertise in research and materials science with extensive experience in manufacturing and product development, Dynasil is commercializing products including dual-mode radiation detection solutions for Homeland Security and commercial applications and sensors for non-destructive testing. Dynasil has an impressive portfolio of issued and pending U.S. patents. The Company is based in Concord, MA, with additional operations in MA, NJ, and the United Kingdom. More information about the Company is available at www.dynasil.com.
## Recent Company News
- 2026-07-09 00:01 EST — [Dynasil Appoints Nirmal Parikh, VP of Marketing - Dynasil Corporation](https://biopharmsignal.com/news/DYSL/dynasil-appoints-nirmal-parikh-vp-of-marketing-dynasil-corporation-261ff65b) — Source: Dynasil
- 2026-07-09 00:01 EST — [Dynasil Corporation of America Announces Results of Tender Offer - Dynasil Corporation](https://biopharmsignal.com/news/DYSL/dynasil-corporation-of-america-announces-results-of-tender-offer-dynasil-corpora-9e5649f0) — Source: Dynasil
- 2026-07-09 00:01 EST — [Dr. Matthew Dallimore Appointed President of Dynasil - Dynasil Corporation](https://biopharmsignal.com/news/DYSL/dr-matthew-dallimore-appointed-president-of-dynasil-dynasil-corporation-61b6cb48) — Source: Dynasil
- 2021-01-07 15:35 EST — [Dynasil Appoints Militram Futuristic Technologies to Target Israel’s Fast Growing Industrial, Commercial and Military Segments - Dynasil Corporation](https://biopharmsignal.com/news/DYSL/dynasil-appoints-militram-futuristic-technologies-to-target-israel-s-fast-growin-63a4781e) — Source: Dynasil
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)